Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing–remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly  by Dwyer, Michael G. et al.
Journal of Neuroimmunology 281 (2015) 44–50
Contents lists available at ScienceDirect
Journal of Neuroimmunology
j ourna l homepage: www.e lsev ie r .com/ locate / jneuro imAssociations between changes in ferritin levels and
susceptibility-weighted imaging ﬁltered phase in patients with
relapsing–remitting multiple sclerosis over 24 weeks of therapy with
subcutaneous interferon beta-1a three times weeklyMichael G. Dwyer a,b,⁎, Robert Zivadinov a,b, Silva Markovic-Plese c,d, Niels Bergsland a, Mari Heininen-Brown a,
Ellen Carl a, Cheryl Kennedy a, Bianca Weinstock-Guttman e, Brooke Hayward f, Fernando Dangond f
a Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York at Buffalo, 100 High St., Buffalo,
NY 14203, USA
b MR Imaging Clinical Translational Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, 100 High St., Buffalo, NY 14203, USA
c Department of Neurology, University of North Carolina at Chapel Hill, 125 Mason Farm Rd., 6109D Neuroscience Research Bldg, CB #7125, Chapel Hill, NC 27599, USA
d Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, 125 Mason Farm Rd., 6109D Neuroscience Research Bldg, CB #7125, Chapel Hill, NC 27599, USA
e Baird MS Center, Department of Neurology, State University of New York at Buffalo, 100 High St., Buffalo, NY 14203, USA
f EMD Serono, Inc., One Technology Pl., Rockland, MA 02370, USA⁎ Corresponding author at: Buffalo Neuroimaging A
Neurology, School of Medicine and Biomedical Sciences,
Buffalo, 100 High St., Buffalo, NY 14203, USA.
E-mail addresses:mgdwyer@bnac.net (M.G. Dwyer), r
(R. Zivadinov),markovics@neurology.unc.edu (S. Markovi
(N. Bergsland), mari.hhb@live.com (M. Heininen-Brown),
ckennedy@bnac.net (C. Kennedy), Bweinstock-guttman@
(B. Weinstock-Guttman), brooke.hayward@emdserono.co
fernando.dangond@emdserono.com (F. Dangond).
http://dx.doi.org/10.1016/j.jneuroim.2015.03.002
0165-5728/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 23 December 2014
Received in revised form 24 February 2015
Accepted 2 March 2015
Keywords:
Multiple sclerosis
Iron deposition
MRISubanalysis of a pilot study (NCT01085318) assessed correlations between serum ferritin and imaging
assessments in relapsing–remitting multiple sclerosis patients (n = 23) receiving 44 μg interferon beta-1a
subcutaneously three times weekly. At baseline, 12, and 24 weeks, mean ferritin was 75, 127 (p b 0.001 vs
baseline), and 101 (p = 0.020 vs baseline) ng/mL. No relationship between ferritin and susceptibility-
weighted imaging (SWI)-ﬁltered phase of subcortical deep gray matter was found. Increasing ferritin correlated
with decreasing lesion numbers on both ﬂuid attenuated inversion recovery and SWI phase at 12 weeks
(r = −0.62; p = 0.003; n = 21), and with decreasing gadolinium-enhancing lesion volume at 24 weeks
(r =−0.71; p = 0.050; n = 8).
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Ferritin is the principal intracellular iron storage protein, acting as a
buffer both to ensure that iron is available when needed and to prevent
iron overload. Each of these roles is vital: iron is essential for a number
of key metabolic processes, including oxidative phosphorylation and
DNA synthesis; it is also integral to the formation of myelin (Da Costa
et al., 2011). However, excessive iron produces damaging reactive
oxygen species through the Fenton reaction. Increased serum ferritin
is usually associated with inﬂammation, infections, and malignancies,
where it is thought to play an adaptive role by reducing the availability
of iron to malignant cells. However, increases have also been correlatednalysis Center, Department of
State University of New York at
zivadinov@bnac.net
c-Plese), npbergsland@bnac.net
ecarl@bnac.net (E. Carl),
kaleidahealth.org
m (B. Hayward),with disease activity in autoimmune diseases such as systemic lupus
erythematosus (Zandman-Goddard and Shoenfeld, 2008).
Hyperferritinemia has also been reported in patients with multiple
sclerosis (MS); in particular, serum ferritin levels have been found to
be abnormally increased in patients with progressive MS (Da Costa
et al., 2011; Sena et al., 2008). However, previous investigations have
found patients with stable or relapsing–remitting MS (RRMS) to show
no signiﬁcant ferritin elevation versus healthy controls (Da Costa et al.,
2011; Sena et al., 2008). Up-regulation of ferritin expression may be
a protective response against oxidative damage from free iron
(LeVine and Chakrabarty, 2004; Sena et al., 2008), and apoferritin has
been shown to reduce disease activity in an animal model (LeVine
et al., 2002). Previous research has shown that interferon beta-1a
administered subcutaneously three times weekly (IFN β-1a SC tiw)
increases serum ferritin level in patients with RRMS in follow-up up to
12 months after beginning treatment, although no correlation with
clinical outcomes was seen in the 43 patients studied and magnetic
resonance imaging (MRI) imagingwas not performed (Sena et al., 2008).
Susceptibility-weighted imaging (SWI)-ﬁltered phase, an indirect
measure indicative of iron deposition, is particularly useful for obtaining
images within subcortical deep gray matter (SDGM) tissue (Haacke
Fig. 1. Representative SWI phase image with speciﬁc segmented structures overlaid
(thalamus in green, putamen in magenta, globus pallidus in dark blue, and caudate in
light blue). On the left side of the ﬁgure, outlines are shown to allow visualization of the
phase contentof structures.Darker regions are indicativeofhigher susceptibility andpotential-
ly higher iron content. SWI: susceptibility-weighted imaging.
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more sensitive detection of tissue changes indicative of iron than may
be obtained with T2 hypointensity or relaxometry measurements
(Haacke et al., 2004, 2009b; Zivadinov et al., 2012). Changes in
SWI-ﬁltered phase can be used to provide additional information to
complement more traditional MRI measurements, such as T1 and
gadolinium-enhancing (Gd+) lesions.
Perhaps due to the recency of phase imaging, the complex relation-
ship between the immune system, ferritin, and brain iron in vivo
is poorly understood. To our knowledge, no studies have directly
investigated the relationship between changes in ferritin and changes
in brain iron. Since ferritin is potentially protective but also upregulated
in pathology, it is not even clear a priori whether such relationships
(if any) would be positive or negative. Therefore, this substudy was
conducted to assess the possible relationship of abnormal (elevated) fer-
ritin levels to SWI and conventionalMRI endpoints in patientswith RRMS
receiving IFN β-1a SC tiw, with the null hypothesis of no relationship
between serum ferritin levels and brain iron or MRI endpoints.
2. Material and methods
Data were obtained from a 24-week, non-randomized, open-label,
two-arm pilot study (ClinicalTrials.gov ID: NCT01085318) of patients
with RRMS receiving IFN β-1a SC tiw (n = 23) and healthy controls
(n=15) (Zivadinov et al., 2014). The trialwas conducted in accordance
with the International Conference on Harmonization guidelines for
Good Clinical Practice and applicable local regulations, as well as the
Declaration of Helsinki. Patients gave written informed consent before
participation and the protocolwas approved by theUniversity at Buffalo
Health Sciences Institutional Review Board. Screening occurred within
2 weeks before a patient entered the study.
Patients were eligible for inclusion if theywere 18–65 years old, with
a diagnosis of RRMS according to the McDonald 2010 criteria (Polman
et al., 2011) and disease duration b20 years, and were treatment-naïve
or using any of the US Food and Drug Administration-approved
disease-modifying drugs (except natalizumab, mitoxantrone, or IFN β-
1a SC tiw). Patients were excluded if they had had a relapse within
30 days prior to screening or had received any of the following treat-
ments: IFNβ-1a SC tiw, intravenous immunoglobulin, or plasmapheresis
within 3 months prior to screening; immunosuppressant agents
(eg, mitoxantrone) or any other concomitant immunomodulatory
therapies (eg, natalizumab) within 30 days prior to screening; or steroid
treatment within 30 days prior to MRI. Other key exclusion criteria
were: alanine aminotransferase N 2.5 × upper limit of normal (ULN),
alkaline phosphatase N 2.5 × ULN, total bilirubin N 1.5 × ULN, total
white blood cell count b 3.0 × 109/L, platelet count b 75 × 109/L,
hemoglobin b 100 g/L, complete transverse myelitis, simultaneous-
onset bilateral optic neuritis, thyroid dysfunction, moderate-to-severe
renal impairment, history of seizures not adequately controlled by
treatment, and any serious or acute cardiac disease.
Baseline assessments included physical and neurological exams,MRI
scans, and laboratory tests. Blood was drawn for standard laboratory
assessments (including iron) and special chemistries (including
ferritin) at screening, 12 weeks, and 24 weeks; samples were sent to
a central laboratory (Quest Diagnostics, Pittsburgh, PA, USA). Neuroim-
aging assessments were performed at baseline, Week 12, and at the
Week 24/Exit Visit. MRI analyses were rater-blinded. Neurological
examinations (which were not blinded) were conducted at screening
and the Week 24/Exit Visit. Patients received a safety evaluation
telephone call at Week 28 (4 weeks after study exit). Patients received
IFNβ-1a SC tiw for 24weeks titrated over 4weeks to aﬁnal dose of 44 μg.
2.1. Data collection
All MRI scans were carried out on a 3 Tesla (3 T) GE Signa Excite HD
12.0 (General Electric,Milwaukee,WI, USA) using amulti-channel headand neck coil. SWI was acquired using a three-dimensional ﬂow-
compensated gradient echo sequence with 64 slices, 2-mm slice
thickness, ﬁeld of view (FOV) = 25.6 cm × 19.2 cm, and an in-plane
resolution of 0.5 mm × 1 mm (ﬂip angle = 12°; TE/TR = 22/40 ms;
acquisition time = 8:46 min:s, bandwidth = 13.89 kHz) (Zivadinov
et al., 2012, 2014). Conventional two-dimensional scans (protondensity
[PD]/T2, ﬂuid attenuated inversion recovery [FLAIR], and T1 SE pre- and
post-contrast) were acquired with consistent voxel size (48 slices of 3-
mm slice thickness, with FOV = 25.6 cm, matrix = 256 × 256, and
phase FOV = 0.75). Patients received a single dose (0.1 mmol/kg)
of Gd contrast. Moreover, a three-dimensional high-resolution
T1-weighted image (WI) fast spoiled gradient echo sequence with
a magnetization-prepared inversion recovery pulse was acquired
(TE/TI/TR = 2.8/900/5.9 ms, ﬂip angle = 10°) using 184 1-mm slices,
resulting in isotropic resolution. All scans were prescribed parallel to
the subcallosal line in an axial-oblique orientationwith a single average.
Segmentation of SDGM structures for SWI analysis was done using
FMRIB's Integrated Registration and Segmentation Tool (FIRST) on the
three-dimensional T1-WI (Patenaude et al., 2011). Additional structures
(red nucleus, pulvinar nucleus, and substantia nigra) not identiﬁable
by this method were manually delineated on the most representative
SWI-ﬁltered phase slice using JIM5 (Xinapse Systems Ltd., Northamp-
tonshire, UK), as reported previously (Zivadinov et al., 2012). Resulting
segmentations were subsequently aligned to SWI phase images using
a combination of FSL's linear image registration tool (FLIRT) and non-
linear image registration tool (FNIRT). An overview of the analysis
method and reproducibility results used in the present study is
discussed elsewhere (Zivadinov et al., 2012). Fig. 1 shows SWI-ﬁltered
phase of the SDGM, with representative segmented regions overlaid.
Phase white matter (WM) lesions were classiﬁed using a manual
region-of-interest approach previously shown to be reproducible
(Hagemeier et al., 2012, 2014). Image analyses were carried out by a
single operator who was blinded to clinical status. WM lesions were
identiﬁed separately on T2/PD/FLAIR, T1-WI, and SWI-ﬁltered phase
maps without a priori knowledge of where the WM lesions were
located with respect to the other modalities. Only round/oval WM
lesions ≥3 mm in diameter were included in the study. In addition, a
Table 1
Baseline characteristics and drug exposure/compliance of patients with RRMS.
Patients with RRMS
n = 23
Mean (SD) age, years 39.9 (10.17)
Female, n (%) 14 (61)
Race, n (%)
Caucasian 20 (87)
African American 3 (13)
Mean (SD) years since MS diagnosis, range 6.6 (5.65), 0–20
Mean (SD) years since most recent relapse, range 1.0 (1.14), 0.1–5.0
Mean (SD) number of relapses in past 12 monthsa 1.3 (1.18)
0, n (%) 7 (30)
1, n (%) 7 (30)
2, n (%) 7 (30)
4, n (%) 2 (9)
Most recent DMD use, n (%)
IFN β-1a IM 8 (35)
IFN β-1a SC 5 (22)
Glatiramer acetate 4 (17)
Natalizumab 2 (9)
IV immunoglobulin 1 (4)
None 3 (13)
Median (range) EDSS score 2.5 (1–5.5)
Mean (SD) serum ferritin, ng/mL 74.7 (75.30)
Mean (SD) Median (range)
T2 lesion number 34.9 (24.51) 28.0 (5.0–115.0)
T2 lesion volume, mm3 23,683 (27,730.6) 17,739 (558–118,940)
T1 lesion number 19.5 (15.34) 19.0 (0.0–59.0)
T1 lesion volume, mm3 4532 (5417.4) 2847 (0–23,364)
Gd+ lesion number 1.8 (4.84) 0.0 (0.0–22.0)
Gd+ lesion volume, mm3 240 (646.4) 0 (0–2915)
SWI lesion number 17.4 (14.47) 16.5 (2.0–68.0)
SWI lesion volume, mm3 2620 (2289.6) 2553 (43–9763)
Number of lesions on overlapping
SWI and FLAIR
16.6 (15.03) 16.5 (1.0–71.0)
Volume of lesions on overlapping
SWI and FLAIR, mm3
1342 (1555.9) 984 (11–6811)
Study drug exposure and
complianceb
IFN β-1a SC tiw
n = 23
8.8 μg 22 μg 44 μg
Mean (SD) total dose received, μg 52.5 (7.60) 133.9 (9.17) 2174.9 (584.47)
Mean (SD) doses missed 0 (0.2) 0 (0) 5 (7.6)
Mean (SD) compliance, % 99 (3.5) 100 (0) 92 (12.2)
DMD: disease-modifying drug; EDSS: Expanded Disability Status Scale; FLAIR: ﬂuid
attenuated inversion recovery; Gd+: gadolinium-enhancing; IFN β-1a: interferon beta-
1a; IM: intramuscularly; IV: intravenous; MS: multiple sclerosis; RRMS: relapsing–remitting
multiple sclerosis; SC: subcutaneously; SD: standard deviation; SWI: susceptibility-
weighted imaging; tiw: three times weekly.
a Patients reported the same number of relapses for the past 24 months.
b Compliance was calculated at study visits using patient diaries and returned drug.
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FLAIR, and a subset was visible on both SWI-ﬁltered phase and T1-WI;
these were identiﬁed a posteriori as overlapping when one or more
voxels overlapped after unblinding was performed.
Images and WM lesion maps for each patient were co-registered
with FMRIB's FLIRT using 6-degrees-of-freedom (rigid-body)
(Jenkinson and Smith, 2001). Images were re-sampled using tri-linear
interpolation and WM lesion maps were re-sampled with nearest-
neighbor interpolation using the registration matrix from their source
images. A semi-automated edge detection contouring/thresholding
techniquewas used to identifyWM lesions (Zivadinov et al., 2001, 2012).
Post-processing of the SDGMwas performed to identify voxels likely
to contain abnormally high amounts of iron based on their phase values.
Reference phase values for each SDGM structure were determined
previously using a large sample of healthy controls (Zivadinov et al.,
2012). Only the voxels of SDGM structures with phase values lower
than two standard deviations (SDs) below the reference group were
retained, yielding structure-speciﬁc maps of voxels with abnormally
low phase. Subsequently, as a measure of the level of phase decrease,
the mean value of sub-threshold voxels was calculated to yield the
mean phase of low phase voxels (MP-LPV). Mean phase and MP-LPV
values were calculated in radians, with lower mean phase and MP-LPV
values suggesting increased iron content.
2.2. Statistical methods
Sample size was based on clinical rather than statistical consider-
ations. Twenty-ﬁve patients with RRMS were planned for inclusion in
the intent-to-treat population (Zivadinov et al., 2014). Changes in
serum ferritin and iron levels from baseline to Week 12 and Week 24
for patients with RRMSwere analyzed using paired t-tests. The possible
relationship of change in ferritin levels with iron levels and with
MRI endpoints was assessed in patients with RRMS using Spearman's
correlation coefﬁcient.
3. Results
Demographic and baseline characteristics of patients with RRMS are
shown in Table 1.
3.1. Changes in ferritin and iron levels
Of the 23 enrolled patients, ferritin levels were missing for one
patient at 12 weeks and for one other patient at 24 weeks. Mean (SD)
ferritin at baseline was 74.7 (75.30) ng/mL; this increased to 127.2
(109.18) ng/mL at 12 weeks (p b 0.001 vs baseline) and decreased to
101.2 (99.57) ng/mL at 24 weeks (p = 0.020 vs baseline; p = 0.034
vs 12 weeks). Fig. 2 shows changes in ferritin levels over the course of
the study. Ferritin level at 12 weeks was higher than at baseline for all
but one patient (out of 22). Ferritin levels for 15/21 patients decreased
from 12 to 24 weeks but were still above baseline levels at Week 24
for 15/22 patients. Ferritin levels were elevated above the ULN range
(232 ng/mL for women and 345 ng/mL for men) for only one woman
(at Week 12 only) and one man (at Weeks 12 and 24).
At baseline,mean (SD) serum iron levelwas 87.7 (36.97) μg/dL; over
12weeks this decreased to 84.0 (40.26) μg/dL (p=0.652). By 24weeks,
serum iron increased to amean of 96.7 (39.29) μg/dL, amean increase of
8.1 (39.80) μg/dL from baseline (p = 0.351 vs baseline). No correlation
was seen between serum iron and ferritin levels at any timepoint
(r = 0.04 [p = 0.866] at baseline; r =−0.26 [p = 0.248] at Week 12;
and r = 0.17 [p = 0.457] at Week 24).
3.2. Ferritin and MRI endpoints
No relationship between changes in serum ferritin and SWI-ﬁltered
phase of the SDGM was found. Fig. 3 shows change in ferritin and MP-LPV of the entire SDGM from baseline toWeek 24. No signiﬁcant change
from baseline was seen in MP-LPV of the SDGM (mean [SD] Week 24
change from baseline, 0.0009 [0.0217] radians).
There was an inverse correlation (r =−0.62; p = 0.003; n = 21)
between change in ferritin level and the number of overlapping SWI
phase and FLAIR lesions after 12 weeks of therapy (i.e., as ferritin level
increased, the number of overlapping SWI phase and FLAIR lesions
decreased; Fig. 4A). There was no correlation between these two
measures after 24 weeks (Fig. 4B).
There was a borderline statistically signiﬁcant positive correlation
(r = 0.44; p = 0.047; n = 21) between ferritin level and absolute
change in T1 lesion volume after 24 weeks (ie, increase in ferritin level
correlated with an increase in T1 lesion volume; Fig. 5). There
was also a borderline signiﬁcant negative correlation (r = −0.71;
p = 0.050) between ferritin and percentage change in Gd+ lesion
volume after 24 weeks among the eight patients with Gd+ lesions at
baseline (Fig. 6). No other signiﬁcant correlations were seen between
changes in serum ferritin level and lesion number or volume.
Ferritin at BL Ferritin at
12 weeks
Ferritin at
24 weeks
p<0.001 p=0.034
400
300
200
100
127
101
75
0
n
g/
m
L
Fig. 2. Ferritin levels over the course of the study. “+” signs represent mean serum ferritin
values observed at each timepoint (75, 127, and 101 ng/mL at BL, 12 weeks, and 24 weeks
respectively); p-values are for the change from 0 to 12 weeks and 12 to 24 weeks.
Red circles represent values above the upper limit of normal (232 ng/mL for women
[one patient at Week 12 only] and 345 ng/mL for men [one patient at Weeks 12 and 24]);
green circles represent values below the lower limit of normal (10 ng/mL for women
[one patient for all timepoints and one patient at BL only]; no measurements were below
the lower limit of normal for men in this study). BL: baseline.
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Almost all patients with RRMS (22/23) had≥1 treatment-emergent
adverse event, as previously reported (Zivadinov et al., 2014). As–0.06
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Fig. 3. Change from 0 to 24 weeks in MP-LPV of total SDGM versus change from 0 to 24 weeks
mean phase of low phase voxels; SDGM: subcortical deep gray matter.expected, injection-site reactions and inﬂuenza-like illness were the
most commonly occurring events.
4. Discussion
In this substudy of a 24-week, non-randomized, single-center trial,
patients with RRMS experienced increases in serum ferritin level after
initiation of treatment with IFN β-1a SC tiw. However, these increases
did not appear to be associated with increased iron deposition in the
SDGM or lesion formation, as assessed by SWI-ﬁltered phase. Previous
research has indicated that the effects of IFN β-1a SC tiw include
increases in serum ferritin and decreases in early lesion formation
(Bastianello et al., 2011; Li et al., 1999; Sena et al., 2008). This is
consistent with the observations from this analysis, in which ferritin
increase was correlated with reductions in lesions simultaneously
visible on FLAIR and SWI-phase, and with reductions in Gd+ lesion
volume.
In this substudy, changes in serum ferritin were not accompanied by
changes in serum iron. Past research has found a lack of serum iron
elevation in patients with MS, even among patients with progressive
disease who had elevated serum levels of ferritin (Abo-Krysha and
Rashed, 2008; Sfagos et al., 2005). Furthermore, since serum iron is
subject to active transport via carrier molecules rather than directly
crossing the blood–brain barrier (Moos et al., 2007), the relationship
between serum iron or ferritin levels and brain iron is complex. For
example, in elderly healthy volunteers, a relationship was shown
between serum iron and deep gray matter iron, but there was no
corresponding relationship with serum ferritin (House et al., 2010).
However, in mice fed a short-term iron-overload diet, serum iron and
liver iron were signiﬁcantly increased, but there was no change in
brain iron level (Johnstone and Milward, 2010). In this study, we had
a unique opportunity to combine blood assays and MRI analysis
to study both serum changes and iron-sensitive MRI phase data. SWI-
ﬁltered phase is inﬂuenced by local magnetic ﬁeld changes caused by
paramagnetic substances such as ferritin, and thus has been proposed
as a method of indirectly measuring increases in iron content in vivo
(Haacke et al., 2004; Hagemeier et al., 2013a). In this study, decreases
in MP-LPV (mean phase values of only those voxels with phase values
more than two SDs from themean value observed among the reference
group) (Hagemeier et al., 2013a; Zivadinov et al., 2012) were used as a
measure of iron content increase in brain structures. Iron would be the
most likely cause of such changes in mean phase measures, although
other factors including the diamagnetic properties of myelin andto 24 weeks (ng/mL)
r=0.14; p=0.532; n=21
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Fig. 4. Change in lesion number on overlapping SWI phase and FLAIR versus change in serum ferritin level over A) 0–12 weeks and B) 0–24 weeks. BL: baseline; FLAIR: ﬂuid attenuated
inversion recovery; SWI: susceptibility-weighted imaging.
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et al., 2011; Langkammer et al., 2010; Yao et al., 2012; Schweser et al.,
2011, 2013). After 24weeks of IFNβ-1a SC tiw treatment, the signiﬁcant
changes in ferritin were not accompanied by any signiﬁcant change in
MP-LPV of the SDGM in this study, and there was no correlation
observed between changes in MP-LPV in the SDGM and serum ferritin.
There are a number of possible explanations for this lack of correla-
tion. First, the blood–brain barrier may insulate the brain from changes
in the serum. Although this has not been directly investigated in MS,
cerebrospinal ﬂuid and serum ferritin assessments have yielded
dramatically different results in other diseases such as restless leg
syndrome (Earley et al., 2000). Second, it is important to note that
although MRI phase-based techniques are highly sensitive to iron,
they are not able to reliably distinguish among the different forms of
iron (e.g., between free iron, transferrin, ferritin, and hemosiderin).
Future studies with further advances in MRI techniques may be able
to investigate this. Finally, it is important to note that thiswas a relative-
ly small subanalysis of a pilot study, and subtle changes below our
statistical threshold cannot be ruled out.
In MS lesions, oligodendrocyte destruction and demyelination can
liberate iron bound to ferritin and permit it to be transformed into
reactive species that can amplify oxidative damage and cellular injury
(Lassmann, 2011). The precise pathophysiological signiﬁcance of the
iron accumulation seen in some, but not all, MS lesions remains
uncertain (Bian et al., 2013; Mehta et al., 2013). It may be indicative of
debris from breakdown of myelin or oligodendrocytes, accumulation
in microglia/macrophages, or leakage from compromised blood vessels,
or it may have a causal role in brain pathology (Haacke et al., 2009a;
Mehta et al., 2013; Hametner et al., 2013). Phase lesions may indicate
the presence of iron, but they are possibly even more affected by
changes in myelin (Bian et al., 2013; Chen et al., 2014; Wen et al.,
2014; Yao et al., 2012). The WM lesion changes seen in this study
could be related to the dual effect of IFN β-1a SC tiw on both iron and
myelin content (Bian et al., 2013; Eissa et al., 2009; Haacke et al.,
2009a; Hagemeier et al., 2014; Mehta et al., 2013; Yablonskiy et al.,
2012; Yao et al., 2012). It is worthwhile to note that ferritin receptors
are abundant in the white matter and that their distribution is reduced
in and around MS lesions (Hulet et al., 1999).From a clinical perspective, the implication of this study is that
therapy-related changes in serum ferritin do not appear to have a
substantial impact on brain iron homeostasis in the short term. The
precise role of iron in multiple sclerosis is still poorly understood,
since iron can play a negative role in the formation of reactive oxygen
species, but is also essential for oligodendrocyte function and
myelination. Therefore, such a lack of interference is potentially
comforting in the absence of a precise understanding of ideal brain
iron levels.
The short duration and small sample size of this analysis are
limitations of this study. No RRMS group receiving placebo was
included. However, the results of this study can be used to guide further
exploration of effects of therapy on ferritin levels in patients with RRMS
and the possible contributions of ferritin and iron to phase lesion
development.5. Conclusions
IFN β-1a SC tiw therapy was associated with short-term increases in
serum ferritin levels and reductions in lesions simultaneously visible on
FLAIR and SWI phase. This association and the correlation of reduced
Gd+ lesionswith ferritin increase are consistentwith previous research
that found IFN β-1a SC tiw to increase serum ferritin and decrease early
lesion formation, while an explanation for the positive correlation seen
between ferritin and T1 lesion volume requires further investigation.
The increases in serum ferritin levels seen were not associated with
signiﬁcant increases in serum iron or with concurrent iron deposition
in the SDGM, as indicated by SWI. These data suggest that increased
serum ferritin after initiation of IFN β-1a SC tiw does not contribute to
brain iron accumulation or lesion formation. In fact, the increase in
ferritin induced by IFN β-1a SC tiw was associated with a reduction in
iron-containing lesions by overlapping SWI and FLAIR, although
signiﬁcant correlation was only seen over the ﬁrst 12 weeks of
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